Abstract:Alcohol-associated hepatitis (AH) is associated with increased short-term mortality in the presence of infections and rapid onset of extrahepatic organ failure driven by intestinal dysbiosis. [ 1 ] Deleterious modifications of the gut microbiota (GM) which include bacteria, fungi, and viral groups in the presence of alcohol are well documented across multiple studies globally. [ 2 ] Gut microbiota contributes to individual susceptibility to alcohol-related liver disease (ALD) and AH through detrimental changes to immune signaling, functional metabolism, and the gut–brain axis. [ 3 ] Specific bacterial taxa have been shown to affect the promotion, progression, and clinical events associated with ALD and AH. For example, in the presence of alcohol, pathogenic bacteria, such as Acinetobacter baumannii enhance their virulence. Alcohol use reduces bacterial diversity, decreases the abundance of beneficial Bacteroidetes, and increases that of pathogenic Proteobacteria, as demonstrated by a significant decrease in Ruminococcaceae and an increase in both Lachnospiraceae and Enterobacteriaceae. [ 4 , 5 ] Alcohol-induced GM dysbiosis leads to liver damage owing to the proliferation of harmful microorganisms that produce exotoxins. One such exotoxin, cytolysin, secreted by Enterococcus faecalis , can directly harm hepatocytes. A higher presence of cytolysin-positive Enterococcus faecalis correlates with greater severity of liver disease and elevated mortality rates in patients with AH. [ 6 ] Specific GM, their interactions, and metabolites are associated with complications of AH and the corresponding treatment outcomes. [ 7 ] Similarly, fungal dysbiosis and fungal metabolites affect the severity of AH. The burgeoning field of research on fungal dysbiosis and proliferation of specific fungal species in ALD has revealed significant findings. Elevated serum levels of anti- Saccharomyces cerevisiae immunoglobulin G antibodies, which indicate a systemic immune response to fungi and their byproducts, are observed in patients with alcohol use disorder and ALD. In patients with AH, heightened serum anti- Saccharomyces cerevisiae immunoglobulin G antibodies levels are associated with increased mortality. Additionally, a higher relative abundance of specific fungal species, such as Candida albicans and Malassezia restricta in the gut, correlates with more severe liver injury and increased mortality in ALD patients. [ 8–10 ] Preliminary studies have shown that patients with ALD and AH can benefit from GM modulation. Clinical trials have explored the use of fecal microbiota transplantation (FMT) to alter the gut microbiome of patients with AH. Studies have demonstrated that AH patients who received FMT from healthy donors exhibited lower rates of alcohol relapse, infections, or hospitalizations; higher rates of resolution of hepatic encephalopathy and ascites; and improved survival in both the short and long term when compared to standard medical care, including pentoxifylline therapy. [ 11–13 ] Another randomized controlled study included 120 patients with AH who received either prednisolone or a healthy donor FMT. Patients receiving FMT had better 90-day survival rates and a reduced incidence of infections compared to those receiving prednisolone. [ 14 ] Probiotics have been shown to improve clinical outcomes in alcohol-associated cirrhosis, and foundational evidence supports their positive effects on GM. Preliminary evidence also supports the beneficial effects of probiotic therapy on GM in AH. [ 15 , 16 ] Nonetheless, the validated and replicated benefits of probiotic therapy and their impact on survival in the context of GM modulation remain unknown. Similarly, probiotic therapy-related modifications within fungal communities, fungal–bacterial interactions, and associated clinical outcomes in AH are enigmatic. We aimed to study the clinical outcomes and GM changes in AH patients receiving high-dose probiotic infusion (HDPI) compared to corticosteroid therapy (CST). Additionally, survival outcomes compared with matched patients undergoing healthy donor FMT were also analyzed. We also studied mycobiome (fungal) community changes and their interactions among patients with AH in the context of HDPI and CST therapies.

Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial

S1870 Fecal Microbiota Transplantation: A Potential Game Changer for Severe Alcoholic Hepatitis? A Systematic Review and Meta-Analysis

Impact of fecal microbiota transplantation in severe alcoholic hepatitis: A systematic review and meta-analysis

Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala

Clinical outcomes and associated bacterial and fungal microbiota changes after high dose probiotic therapy for severe alcohol-associated hepatitis: An observational study

3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation

Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease with Fecal Microbiota Transplantation: A Pilot Study

Granulocyte colony stimulating factor improves Prednisolone responsiveness and 90-day survival in steroid eligible severe Alcohol associated Hepatitis: The GPreAH Study a randomized trial

Expedited liver transplantation as first‐line therapy for severe alcohol hepatitis: ELFSAH; deferring corticosteroids in the sickest subset of patients

Serum bile acids profiles are altered without change of the gut microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis

Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial

Granulocyte Colony-Stimulating Factor in Severe Alcoholic Hepatitis: A Randomized Pilot Study

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study

The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial

Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD: Interim Results a Non-randomized, Open-label, Phase 1 Clinical Study

Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice

Therapeutic effects of fecal microbial transplantation on alcoholic liver injury in rat models

Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis

A Combination of N-Acetylcysteine and Prednisone Has No Benefit Over Prednisone Alone in Severe Alcoholic Hepatitis: A Retrospective Analysis

Research Progress of Fecal Microbiota Transplantation in Liver Diseases

Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance